Marketspace: Leading therapeutic recombinant protein sales forecast and analysis to 2010

Abstract

As part of Datamonitor's biotechnology strategic market analysis, the authors have performed an analysis of the top 20 therapeutic recombinant proteins (defined by 2010 forecast sales), providing a forecast from 2004 to 2010 of product sales by therapeutic and product class. Based on this analysis, which was conducted in June 2005, leading companies operating in this sector are identified. Market analysis indicates that the total compound annual growth rate (CAGR) of these products from 2004 to 2010 is set to be 7.7 per cent, which is lower than other biotech markets such as the monoclonal antibody market. This lower growth rate reflects the mature nature of the therapeutic recombinant protein market. The arthritis, immune and inflammatory disorders franchise is set to record the strongest growth, with a forecast 2004–10 CAGR of 16.8 per cent, while the diabetes and endocrinology franchise is set to record the weakest growth (1.6 per cent). The leading product class in terms of total forecast 2010 sales is the erythropoietin class, which is set to generate approximately one-third of total top 20 product sales. The strongest-growing product classes are set to be fusion protein and colony-stimulating factors, while insulins are forecast to be the weakest-growing sector. Amgen is set to continue to lead the recombinant protein market over the forecast period, with the company's contribution to top 20 recombinant protein market sales set to rise from one-third of total 2004 sales to one-half of total 2010 sales.